Loading clinical trials...
Loading clinical trials...
A Randomized, Double-blind Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Oral NX-13 in Active Ulcerative Colitis
Conditions
Interventions
NX-13 250mg IR
NX-13 500mg IR
+2 more
Locations
31
United States
Avant Research Associates LLC
Huntsville, Alabama, United States
Om Research LLC
Lancaster, California, United States
Allameh Medical Corporation
Mission Viejo, California, United States
California Medical Research Associates, Inc.
Northridge, California, United States
Clinical Research of California
Walnut Creek, California, United States
I.H.S Health LLC
Kissimmee, Florida, United States
Start Date
May 5, 2021
Primary Completion Date
June 17, 2022
Completion Date
October 5, 2022
Last Updated
February 15, 2023
NCT06372613
NCT07550673
NCT07374471
NCT05739864
NCT06071312
NCT04338204
Lead Sponsor
Landos Biopharma Inc.
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions